Session 7: Ubiquitin & Proteasomes

Hershko, A. , and Ciechanover, A. (1998). The ubiquitin system. Annu Rev Biochem 67, 425—79.

Weissman, A.M. (2001). Themes and variations on ubiquitylation. Natl Rev Mol Cell Biol 2, 169—78.

Ciechenover, A. (1998). The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17, 7151—60.

Rock, K.L. et al. (1994). Inhibitors of the proteosome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761—71.

Zwickl, P. , Voges, D. , and Baumeister, W. (1999). The proteasome: a macromolecular assembly designed for controlled proteolysis. Philos Trans R Soc London B Biol Sci 354, 1501—11.

Wilkinson, K.D. (1999). Ubiquitin-dependent signaling: the role of ubiquitination in the response of cells to their environment. J Nutr 129, 1933—6.

DeMartino, G.N. , and Slaughter, C.A. (1999). The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem 274, 22123—6.

Albanell, J. , and Adams, J. (2002). Bortezomib, a proteasome inhibitor in cancer therapy: from concept to clinic. Drugs of the future 27(11), 1079—92.

Elliot, P.J. (1999). Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59, 2615—22.

Sakamoto, K.M. (2002). Ubiquitin-dependent proteolysis: its role in human diseases and the design of therapeutic strategies. Molec Genet Metabol 77, 44—56.

Rolfe, M. , Chiu, M.I. , and Pagano, M. (1997). The ubiquitin-mediated proteolytic pathways as a therapeutic area. J Mol Med 75, 5—17.

Elliott, P.J. , and Zollner, T.M. (2003). Proteasome inhibition: a new antiinflammatory strategy. J Mol Med 81, 235—45.

McBride, W.H. et al. (2003). The role of ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22, 5755—73.

Drexler, H.C. (1997). Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 94, 855—60.

Fang, S. et al. (2003). RING finger ubiquitin protein ligases: implications for tumorogenesis, metastasis and for molecular targets in cancer . Seminars in Cancer Biology, 13, 5—14.

Shinohara, K. et al. (1996). Apoptosis induction resulting from proteasome inhibition. Biochem J 317, 385—8.

Adams, J. , Palombella, V.J. , and Elliot, P.J. (2000). Proteasome inhibition: a new strategy in cancer treatment. Investigational New Drugs 18, 109—21.

Leem, M.-H. , and Yang, H.-Y. (2003). Molecular targets for cell cycle inhibition and cancer therapy. Expert Opin Ther Patents 13(3), 329—46.

Murray, R.Z. , and Norbury, C. (2000). Proteasome inhibitors as anti-cancer agents. Anti-Cancer Drugs 11, 407—17.

Almond, J.B. , and Cohen, G.M. (2002). The proteasome: a novel target for anticancer chemotherapy. Leukemia 16, 433—43.

Cadavid, A.L.M. , Ginzel, A. , and Fischer, J.A. (2000). The function of the Drosophila Fat facets deubiquitinating enzyme in limiting photoreceptor cell number is intimately associated with endocytosis. Development 127, 1727—36.

Chen, X. , Zhang, B. , and Fischer, J.A. (2002). A specific protein substrate for a deubiquitinating enzyme: liquid facets is the substrate of Fat facets. Genes Dev 16, 289—94.

De Camilli, P. , Chen, H. , Hyman, J. , Panepucci, E. , Bateman, A. , and Brunger, A.T. (2001). The ENTH domain. FEBS Lett 25686, 1—6.

Fischer, J.A. (2003). Deubiquitinating enzymes: their roles in development, differentiation, and disease. Int Rev Cytol 229, 43—72.

Fischer, J.A. , Leavell, S. , and Li, Q. (1997). Mutagenesis screens for interacting genes reveal three role for fat facets during Drosophila eye development . Dev Genet 21, 167—74.

Fischer-Vize, J.A. , Rubin, G.M. , and Lehmann, R. (1992). The fat facets gene is required for Drosophila eye and embryo development. Development 116, 985—1000.

Huang, Y. , Baker, R.T. , and Fischer-Vize, J.A. (1995). Control of cell fate by a deubiquitinating enzyme encoded by the fat facets gene. Science 270, 1828—31.

Parks, A.L. , Klueg, K.M. , Stout, J.R. , and Muskavitch, M. A. T (2000). Ligand endocytosis drives receptor dissociation and activation in the Notch pathway. Development 127, 1373—85.

Weissman, A.M. (2001). Themes and variations on ubiquitylation. Nat Rev Mol Cell Biol 2, 169—78.

Weng, A.P. , and Aster, J.C. (2004). Multiple niches for Notch in cancer: context is everything. Curr Opin Genet Dev 14, 48—54.

Wu, Z. , Li, Q. , Fortini, M.E. , and Fischer, J.A. (1999). Genetic analysis of the role of the Drosophila fat facets gene in the ubiquitin pathway. Dev Genet 25, 312—20.

Borden, K.L. (2000). RING domains: master builders of molecular scaffolds? J Mol Biol 295, 1103—12.

Hu, G. , Zhang, S. , Vidal, M. , Baer, J.L. , Xu, T. , and Fearon, E.R. (1997). Mammalian homologs of seven in absentia regulate DCC via the ubiquitinproteasome pathway. Genes Dev 11, 2701—14.

Matsuzawa, S.I. , and Reed, J.C. (2001) Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. Mol Cell 7, 915—26

Habelhah, H. , Takahashi, S. , Cho, S.G. , Kadoya, T. , and Ronai, Z. (2004). TRAF2 ubiquitination is required for its translocation to the cell membrane and activation of JNK but not p38 or NF-□B signaling. EMBO J 23, 322—32.

Habelhah, H. , Frew, I. , Laine, A. , Janes, P. , Relaix, F. , Sassoon D. , Bowtell, D. , and Ze'ev Ronai. (2002). Siah2 as regulator of TRAF2 stability. EMBO J 21, 5756—65.

Ivan, M. , Kondo, K. , Yang, H. , Kim, W. , Valiando, J. , Ohh, M. , Salic, A. , Asara, J.M. , Lane, W.S. , and Kaelin Jr., W.G. (2001). HIF□ targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292, 464—8.

Koh Nakayama, K. , Frew, I.J. , Hagensen, M. , Skals, M. , Habelhah, H. , Erdjument-Bromage , H. , Tempst, P. , Frappell, P.B. , Bowtell, D.D. , and Ronai, Z. (2004). Siah2 regulates stability of the prolyl-hydroxylase SM20, controls HIF1α abundance and modulates physiological responses to hypoxia. Cell, In Press, June 2004.